News &
Media
-
Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism
View More -
Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.
View More -
Stocks Down Under Interview with Neurotech International (ASX:NTI)
View More -
Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
View MoreNeurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
-
Neurotech Releases ASD Medical Cannabis Study Results
View MoreAustralia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.
-
Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD
View More -
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech has released promising results from a world-first study of a medicinal cannabis product which could be a game changer in treating children with autism.
-
Neurotech study finds children with autism benefit from cannabis product
View MoreNeurotech International (ASX:NTI) has today announced its patent NTI164 product has been proven to reduce ASD symptoms in children and teenagers.